Hospital Universitario Reina Sofia -ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

2021

  1. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register

    Arthritis Research and Therapy, Vol. 22, Núm. 1

2019

  1. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

    Rheumatology International, Vol. 39, Núm. 3, pp. 509-515

2015

  1. Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 269-278

  2. Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]

    Seminars in Arthritis and Rheumatism

2011

  1. Eficacia y seguridad de abatacept en pacientes con artritis reumatoide sin tratamiento biológico previo

    Reumatologia Clinica

  2. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology